Astrazeneca Pharma India Q2 Results 2024:Astrazeneca Pharma India declared its Q2 results for 2024 on November 13, revealing a significant increase in revenue but a decline in profit compared to the previous year. The company’s revenue for the quarter stood at ₹408 crore, reflecting a 31.16% year-over-year growth, while profit decreased by 26.62% year-over-year to ₹38.43 crore.
In comparison to the previous quarter, Astrazeneca Pharma India saw a revenue growth of 5.28% and a remarkable profit increase of 425.95%. However, the increase in selling, general, and administrative expenses, which rose by 18.21% quarter-on-quarter and 12.86% year-over-year, contributed to the profit decline.
The operating income demonstrated a substantial improvement, increasing by 284.62% quarter-on-quarter, although it experienced a decline of 34.06% year-over-year. Earnings per share (EPS) for the quarter were reported at ₹15.37, down by 5.48% from the previous year.
In terms of stock performance, Astrazeneca Pharma India has delivered a -9.92% return in the last week, but has shown a positive trend with a 19.83% return over the past six months and a 22.55% year-to-date return. The company currently holds a market capitalization of ₹16,932.38 crore, with a 52-week high of ₹8,139 and a low of ₹4,600.7.
Astrazeneca Pharma India Financials
| Period | Q2 | Q1 | Q-o-Q Growth | Q2 | Y-o-Y Growth |
|---|---|---|---|---|---|
| Total Revenue | 408 | 387.52 | +5.28% | 311.07 | +31.16% |
| Selling/ General/ Admin Expenses Total | 92.57 | 78.31 | +18.21% | 82.02 | +12.86% |
| Depreciation/ Amortization | 9.32 | 3.91 | +138.36% | 3.67 | +153.68% |
| Total Operating Expense | 364.8 | 410.92 | -11.22% | 245.56 | +48.56% |
| Operating Income | 43.2 | -23.4 | +284.62% | 65.51 | -34.06% |
| Net Income Before Taxes | 51.03 | -15.16 | +436.61% | 73.38 | -30.46% |
| Net Income | 38.43 | -11.79 | +425.95% | 52.37 | -26.62% |
| Diluted Normalized EPS | 15.37 | 10.26 | +49.83% | 16.26 | -5.48% |
Disclaimer: This is an AI-generated live blog and has not been edited by LiveMint staff.
